2024.Dec.31

Corporate

OBI Pharma's OBI-992 Research Paper Selected as a First Disclosure Article Featured in Molecular Cancer Therapeutics Journal

OBI Pharma (4174.TWO)'s independent work based on a TROP2-targeted Antibody-Drug Conjugate (ADC) anti-cancer asset, OBI-992, is published in the internationally renowned journal "Molecular Cancer Therapeutics" (MCT), with the article designated as a First Disclosure recommended publication.

HOMEWhat’s NewNewsOBI Pharma’s OBI-992 Research Paper Selected as a First Disclosure Article Featured in Molecular Cancer Therapeutics Journal

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2024.Dec.23

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production